Summary:
- This article discusses the development of a new COVID-19 vaccine candidate that uses a novel approach to induce a strong immune response.
- The vaccine, called RBD-Fc, is designed to target the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, which is a key component for the virus to infect human cells.
- The study shows that the RBD-Fc vaccine elicited a robust antibody response and provided protection against SARS-CoV-2 infection in animal models, suggesting it could be a promising candidate for further development and clinical trials.